Cargando…
Role of Flavonoids in the Prevention of AhR-Dependent Resistance During Treatment with BRAF Inhibitors
BRAF and MEK inhibitors (BRAFi and MEKi) are the standard of care for the treatment of metastatic melanoma in patients with BRAF(V600E) mutations, greatly improving progression-free survival. However, the acquisition of resistance to BRAFi and MEKi remains a difficult clinical challenge, with limite...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404066/ https://www.ncbi.nlm.nih.gov/pubmed/32708687 http://dx.doi.org/10.3390/ijms21145025 |